reports
- Sean Conroy
Brighter - Termination of coverage
Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
- Sean Conroy
Brighter - Termination of coverage
Edison Investment Research is terminating coverage on AdAlta (1AD), Acorn Income Fund (AIF), GCP Student Living (DIGS) and Brighter (BRIG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
- Sean Conroy
Brighter - Poised for revenue momentum
Brighter recently reported its results for the first quarter of 2021 and continues to be poised for revenue momentum at the end of the year. Actiste has market approval in Saudi Arabia, the United Arab Emirates (UAE) and Thailand, as well as a five-year distribution agreement in Qatar and five-year agreements in both Nigeria and Ghana. Once registrations are in place in Nigeria and Ghana, Brighter expects to receive €2.3m (SEK23.4m) and €1.2m (SEK12.2m), respectively, in initial orders in those ...
- Sean Conroy
Brighter - Progress in multiple regions
Brighter has been making progress in multiple regions for Actiste, which now has market approval in Saudi Arabia, the United Arab Emirates (UAE) and Thailand, as well as a five-year distribution agreement in Qatar and five-year agreements in both Nigeria and Ghana. Once registrations are in place in Nigeria and Ghana, Brighter expects to receive €2.3m (SEK23.4m) and €1.2m (SEK12.2m), respectively, in initial orders in those countries. The approval processes in Nigeria and Ghana are expected to b...
- Sean Conroy
Brighter - Approvals in the UAE and Saudi Arabia
Brighter recently announced that both the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) and the Saudi Food and Drug Authority (SFDA) have provided market approvals for the Actiste device. While all necessary regulatory approvals have been obtained in the UAE, commercialisation in Saudi Arabia will require additional regulatory approvals, such as for consumables, but those are expected to be granted in the coming months. Additional registration efforts are also underway in ...
- Sean Conroy
Brighter - Q220 results
Brighter recently announced Q220 results. Not surprisingly, the COVID-19 pandemic has caused some commercialisation delays, especially with the registration of Actiste in the United Arab Emirates (UAE). However, as of May the service is commercially available in Sweden and the company is harvesting user insights that will help it improve the experience over time. Additionally, the company announced a partnership with the provincial government of West Java (population of c 50 million) in Indonesi...
- Sean Conroy
Brighter - Multiple registrations underway
Brighter continues to scale up the commercialization effort for Actiste in the target regions of South-East Asia and the Gulf Cooperation Council (GCC) and, as of May, the service is commercially available in Sweden. Registration is currently underway in Malaysia, Singapore, Thailand, Indonesia and the United Arab Emirates (UAE). The registration process is also about to start in Saudi Arabia, Kuwait, Oman and Bahrain. The company expects Actiste to be commercially available in multiple countrie...
- Sean Conroy
Brighter - Expanding further into assisted care solutions
Brighter initiated activity on multiple fronts following the issue of CE marks for its lead product, Actiste. It acquired Nectarine Health, a Swedish healthtech start-up, to complement its other assisted care solutions acquisition, Camanio. Brighter also entered into a strategic partnership with Accumbo, a digital healthcare provider, to support the visibility of Actiste in the Swedish market, one of Brighter’s target markets. Also, to support commercialisation activities in the near term, the...
- Sean Conroy
Brighter - Executive interview
Brighter is a Swedish healthtech company focused on the development and commercialisation of self-monitoring and self-treatment health solutions for diabetes. Its lead product, Actiste, which recently received two CE marks, combines three critical components of daily diabetes management, a blood glucose meter, a lancet and an injection apparatus into one device with mobile connectivity to Brighter’s cloud-based service, the Benefit Loop. In this video the company discusses how Actiste integra...
- Sean Conroy
Brighter - Moving to commercial status
After receiving two CE marks for the Actiste device, Brighter is registering the product with local authorities in the United Arab Emirates (UAE). On introduction to the market, it will conduct user experience pilot tests to optimise adoption. Following the UAE, the company plans to focus its commercialisation efforts on Sweden, the rest of the Gulf Cooperation Council (GCC) area and South-East Asia (particularly Thailand and Indonesia).
- Maxim Jacobs
Brighter - CE marks for Actiste device received
Brighter recently announced that it has received CE marking for the Actiste device. In fact, it has received two CE marks as Actiste is regulated under both the EU Medical Devices Directive and the In Vitro Diagnostics Directive due to the multiple functions of the device. Initially, the company will focus on establishing service in the Gulf Cooperation Council (GCC), especially the United Arab Emirates (UAE), Sweden and South-East Asia (in particular Thailand and Indonesia).
- Maxim Jacobs
Brighter - Waiting on the CE mark
Back in December, Brighter announced that all the technical documentation had been submitted to the designated notified body for final approval of a CE mark for the Actiste device. We expect a decision around the end of H119. Initial commercialisation is expected to focus on Gulf Cooperation Council (GCC) countries, especially the United Arab Emirates (UAE). In the interim, management has been working on additional capital injections, including SEK17.5m in Q1 and an additional SEK19.6m after the...
- Maxim Jacobs
Brighter - Recent capital injection to fuel first sales
Towards the tail-end of 2018, Brighter received ~SEK48m of capital injections from a number of sources, mostly from its management incentives programme, and an additional SEK5m in early 2019. The company intends to utilise these proceeds to drive commercialisation in regions of the Gulf Cooperation Council (GCC), specifically the United Arab Emirates (UAE). In December, the company announced that all the technical documentation has been submitted for the CE marking process.
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.